Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508649 | 0.86 | ALDH1A1 (0.46) | GAARXFP1KDM4EKMT2AMEN1 | |
| SCHEMBL3423151 | 0.84 | AR (0.53) | NPSR1GAARXFP1CES2CES1 | |
| SCHEMBL29032337 | 0.82 | AR (0.51) | NPSR1GAARXFP1CES2CES1 | |
| SCHEMBL4909498 | 0.82 | GAA (0.47) | NPSR1GAARXFP1CES2CES1 | |
| SCHEMBL12124279 | 0.79 | KMT2A (0.54) | NPSR1GAAKDM4EDAOKMT2A | |
| SCHEMBL21124416 | 0.79 | KDM4E (0.50) | GAARXFP1KDM4EKMT2AMEN1 | |
| SCHEMBL3427641 | 0.79 | AR (0.49) | NPSR1GAARXFP1CES2CES1 | |
| SCHEMBL3848242 | 0.79 | GAA (0.59) | NPSR1GAARXFP1CES2CES1 | |
| SCHEMBL3241403 | 0.78 | AR (0.52) | NPSR1KDM4EDAOKMT2AMEN1 | |
| SCHEMBL24414750 | 0.76 | AR (0.67) | NPSR1GAARXFP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014157382-A1 | SPHINGOSINE KINASE INHIBITOR | 味の素株式会社 (JP) | 2014-10-02 | — | — | WO | disclosed |
| US-8247409-B2 | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-7745449-B2 | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100125074-A1 | Thieno-[2,3-d]Pyrimidine and Thieno-Pyridazine Compounds and Methods of Use | AMGEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20080032988-A1 | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | AMGEN INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032988-A1 | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | CDK2, TBXA2R, TBXAS1 | NPSR1 2469/4885GAA 4454/4885RXFP1 2639/4885 |
| US-20100125074-A1 | Thieno-[2,3-d]Pyrimidine and Thieno-Pyridazine Compounds and Methods of Use | CDK2, TBXA2R, TBXAS1 | NPSR1 2469/4885GAA 4454/4885RXFP1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.